Following the release of linagliptin phase-II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal phase-III clinical trials. The company confirmed that first results from the phase-III clinical trials programme consistently support the favourable efficacy and safety profile already observed in earlier linagliptin investigational studies, such as the phase-II data which had shown significant results in haemoglobin A1c (HbA1c)-lowering (-0,73 percent, 5 mg dose) and a safety profile comparable to placebo.
The details can be read here.
No comments:
Post a Comment